The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Incyte Corp (NASDAQ: INCY) was $105.7 for the day, up 2.70% from the previous closing price of $102.92. In other words, the price has increased by $2.70 from its previous closing price. On the day, 2.74 million shares were traded. INCY stock price reached its highest trading level at $106.47 during the session, while it also had its lowest trading level at $101.5.
Ratios:
Our analysis of INCY’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.08 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.34. For the most recent quarter (mrq), Quick Ratio is recorded 3.13 and its Current Ratio is at 3.20. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Wells Fargo Upgraded its Equal Weight to Overweight on August 06, 2025, while the target price for the stock was maintained at $89.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 05 ’25 when STEVEN STEIN bought 5,233 shares for $102.20 per share.
Heeson Lee sold 3,074 shares of INCY for $289,017 on Nov 03 ’25. The EVP, Head of Incyte Intl now owns 29,241 shares after completing the transaction at $94.02 per share. On Nov 04 ’25, another insider, SHEILA DENTON, who serves as the Officer of the company, bought 598 shares for $101.36 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INCY now has a Market Capitalization of 20751308800 and an Enterprise Value of 17862756352. As of this moment, Incyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.73, and their Forward P/E ratio for the next fiscal year is 13.93. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.17. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.31 while its Price-to-Book (P/B) ratio in mrq is 4.46. Its current Enterprise Value per Revenue stands at 3.711 whereas that against EBITDA is 13.489.
Stock Price History:
The Beta on a monthly basis for INCY is 0.80, which has changed by 0.24993932 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, INCY has reached a high of $103.86, while it has fallen to a 52-week low of $53.56. The 50-Day Moving Average of the stock is 20.89%, while the 200-Day Moving Average is calculated to be 44.37%.
Shares Statistics:
INCY traded an average of 2.02M shares per day over the past three months and 3464110 shares per day over the past ten days. A total of 196.13M shares are outstanding, with a floating share count of 193.97M. Insiders hold about 1.20% of the company’s shares, while institutions hold 105.12% stake in the company. Shares short for INCY as of 1760486400 were 9364129 with a Short Ratio of 4.64, compared to 1757894400 on 8697013. Therefore, it implies a Short% of Shares Outstanding of 9364129 and a Short% of Float of 6.7299999999999995.
Earnings Estimates
The stock of Incyte Corp (INCY) is currently being evaluated by 15.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $1.63, with high estimates of $1.9 and low estimates of $1.33.
Analysts are recommending an EPS of between $7.16 and $6.62 for the fiscal current year, implying an average EPS of $6.85. EPS for the following year is $7.71, with 21.0 analysts recommending between $9.33 and $5.38.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 19 analysts. It ranges from a high estimate of $1.43B to a low estimate of $1.31B. As of. The current estimate, Incyte Corp’s year-ago sales were $1.18BFor the next quarter, 19 analysts are estimating revenue of $1.25B. There is a high estimate of $1.36B for the next quarter, whereas the lowest estimate is $1.18B.
A total of 21 analysts have provided revenue estimates for INCY’s current fiscal year. The highest revenue estimate was $5.06B, while the lowest revenue estimate was $4.92B, resulting in an average revenue estimate of $4.97B. In the same quarter a year ago, actual revenue was $4.24BBased on 21 analysts’ estimates, the company’s revenue will be $5.51B in the next fiscal year. The high estimate is $5.86B and the low estimate is $5.13B.
